EOM Pharmaceutical Holdings Stock Price, News & Analysis
IMUC
OTC
Company Description
Immunocellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company developing immune-based therapies for brain and other cancers. They've completed phase 2 trials for ict-107, targeting glioblastoma stem cells and have projects like ict-121, ict-140, and stem-to-t-cell research.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$19.1M
Market Cap
113.3M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for EOM Pharmaceutical Holdings.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the current stock price of EOM Pharmaceutical Holdings (IMUC)?
The current stock price of EOM Pharmaceutical Holdings (IMUC) is $0.1377 as of April 24, 2025.
What is the market cap of EOM Pharmaceutical Holdings (IMUC)?
The market cap of EOM Pharmaceutical Holdings (IMUC) is approximately 19.1M.
What is Immunocellular Therapeutics, Ltd. focused on?
They are developing immune-based therapies for brain and other cancers.
What is the lead product candidate of Immunocellular?
Ict-107 is a dendritic cell-based immunotherapy targeting tumor-associated antigens on glioblastoma stem cells.
What other projects are in Immunocellular's pipeline?
They have projects like ict-121, ict-140, and the stem-to-t-cell research program.
Where is Immunocellular Therapeutics, Ltd. based?
They are based in Los Angeles.
What phase of trials has ict-107 completed?
Ict-107 has concluded phase 2 trials.
What is the significance of ict-121?
Ict-121 is a dendritic cell immunotherapy targeting the cd133 antigen on stem cells in recurrent glioblastoma.
What is the focus of ict-140?
Ict-140 is a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells.
What is the stem-to-t-cell research program about?
It engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing t-cells.